SEC Form 4 · accession 0001104659-19-006896
STEMLINE THERAPEUTICS INC · STML
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Gionco
Officer — Chief Accounting Officer
Period of report
Feb 6, 2019
Accepted (ET)
Feb 8, 2019 · 8:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001264587
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Dec 21, 2018 | A | 15,000 | $0.00 | A | 170,345 | D | |
| Common StockF3,F4 | Feb 6, 2019 | A | 69,550 | $0.00 | A | 239,895 | D | |
| Common StockF5,F6 | Feb 6, 2019 | A | 9,009 | $0.00 | A | 248,904 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The 15,000 restricted shares will vest in three installments as follows: 5,000 shares on December 21, 2019; 5,000 shares on December 21, 2020; and 5,000 shares on December 21, 2021.
- F2Of the 170,345 shares, 144,217 shares are restricted stock.
- F3The 69,550 restricted shares will vest in three installments as follows: 23,184 shares on March 31, 2020; 23,183 shares on January 19, 2021; and 23,183 shares on April 12, 2022.
- F4Of the 239,895 shares, 213,767 shares are restricted stock.
- F5The 9,009 restricted shares will vest in two installments as follows: 4,505 shares on December 21, 2019 and 4,504 shares on December 21, 2020.
- F6Of the 248,904 shares, 222,776 shares are restricted stock.